Our Calculation Of Intrinsic Value: Pfizer Inc

Source: DepositPhotos

Each week, we run a DCF (Discounted Cash Flow) model on a company from our watchlist.

This week’s pick: Pfizer Inc. (PFE).

Profile

Pfizer is one of the world’s largest pharmaceutical companies, focused on developing and commercializing medicines and vaccines across oncology, immunology, cardiology, and infectious diseases.

The company gained global prominence during the COVID-19 pandemic through its vaccine and antiviral treatments, which temporarily drove exceptional revenue and cash flow. However, Pfizer has since entered a post-pandemic normalization phase.

Pfizer operates through a research-driven, patent-based model, where profitability depends on:

• Successful drug development pipelines

• Patent protection and exclusivity periods

• Strategic acquisitions (e.g., oncology and specialty pharma)

Pfizer’s competitive advantages include:

• A diversified drug portfolio across multiple therapeutic areas

• Strong R&D capabilities and global clinical infrastructure

• Scale and global distribution reach

• Significant free cash flow generation (though volatile post-COVID)

Pfizer is transitioning back to a traditional large-cap pharma profile: slower growth, patent cliffs, and reliance on pipeline execution.

DCF Analysis

Inputs:

• Discount Rate: 9%

• Terminal Growth Rate: 2%

• WACC: 9%

Forecasted Free Cash Flows (in billions USD)

(Based on normalized post-COVID cash flows and moderate growth)

• 2025: $9.0 → PV: $8.3

• 2026: $9.3 → PV: $7.8

• 2027: $9.6 → PV: $7.4

• 2028: $9.9 → PV: $7.0

• 2029: $10.2 → PV: $6.6

Total Present Value of FCFs = ~$37.1B

Terminal Value Calculation

Using perpetuity growth model with 2029 FCF = $10.2B:

TV = (10.2 × 1.02) ÷ (0.09 − 0.02)
TV ≈ $148.6B

Present Value of Terminal Value ≈ $96.6B

Enterprise Value

Enterprise Value = $37.1B + $96.6B = $133.7B

Net Debt

• Cash & Equivalents: ~$13.6B

• Total Debt: ~$64.0B

Net Debt ≈ $50.4B

Equity Value & Per-Share Value

• Equity Value = $133.7B − $50.4B = $83.3B

• Shares Outstanding: ~5.7B

Intrinsic Value per Share ≈ $14–15

Conclusion

• DCF Value: ~$15

• Current Price: ~$27

• Margin of Safety: ~–45%

Pfizer remains a high-quality pharmaceutical company with global scale, strong R&D capabilities, and a diversified drug portfolio. However, the business is currently navigating a difficult transition following the COVID-era revenue surge.

The key challenge is replacing lost pandemic revenue while managing:

• Patent expirations

• Integration of acquisitions

• Pipeline execution risk

While Pfizer continues to generate solid free cash flow and offers an attractive dividend yield, growth visibility remains uncertain in the near term.

Under conservative assumptions, PFE appears modestly overvalued. The market is pricing in a recovery driven by pipeline execution and new product launches.

For investors, Pfizer sits in a middle ground:

• Not a deep value play yet

• But potentially interesting if pipeline execution improves or valuation compresses further

At current levels, expected returns will likely depend on:

• Dividend yield

• Pipeline breakthroughs

• Gradual earnings recovery rather than multiple expansion